FGF19 and metabolic syndrome: Additionally, fucogalactan sulfate (FS), isolated from Laminaria, has been observed to inhibit the expression of the FXR receptor in the liver and reduce the expression of cholesterol 7α-hydroxylase (CYP7A1) and human sterol 12a-hydroxylase (CYP8B1), potentially decreasing BA synthesis and lipid absorption in mice with humanized dyslipidemia via the FXR-FGF19 signaling pathway [115].